Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Proteogenomics connects somatic mutations to signalling in breast cancer

(2016) Philipp Mertins et al.   NATURE

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

(2016) Mariano J Alvarez et al.   NATURE GENETICS

Functional annotation of rare gene aberration drivers of pancreatic cancer

(2016) Yiu Huen Tsang et al.   Nature Communications

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer

(2015) K. E. Hew et al.   CLINICAL CANCER RESEARCH

Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans

(2015) Can Cenik et al.   GENOME RESEARCH

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

(2015) Lawrence N. Kwong et al.   JOURNAL OF CLINICAL INVESTIGATION

FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance

(2014) Stefania Zona et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

(2014) Lydia W.T. Cheung et al.   CANCER CELL

Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

(2014) C. H. Kugel et al.   CANCER RESEARCH

Forkhead Transcription Factor FOXO3a Levels Are Increased in Huntington Disease Because of Overactivated Positive Autofeedback Loop

(2014) Kaja Kannike et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Genome-wide transcriptome profiling of homologous recombination DNA repair

(2014) Guang Peng et al.   Nature Communications

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities

(2013) Atsushi Shibata et al.   MOLECULAR CELL

Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling

(2013) A. Eijkelenboom et al.   Molecular Systems Biology

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

(2013) N Panupinthu et al.   ONCOGENE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis

(2012) O. Takahashi et al.   CLINICAL CANCER RESEARCH

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer

(2012) H. Liang et al.   GENOME RESEARCH

Ovarian low-grade serous carcinoma: A comprehensive update

(2012) Ivan Diaz-Padilla et al.   GYNECOLOGIC ONCOLOGY

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

(2012) Stephan P Tenbaum et al.   NATURE MEDICINE

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers

(2011) E. Vilar et al.   CANCER RESEARCH

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer

(2011) C T Karadedou et al.   ONCOGENE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases

(2009) Shuying Liu et al.   CANCER CELL

Synthetic Lethality — A New Direction in Cancer-Drug Development

(2009) J. Dirk Iglehart et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

(2008) J. W. Tyner et al.   BLOOD

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE